GO:0032480 negative regulation of type I interferon production: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032480 describes any process that stops, prevents, or reduces type I interferon production, a central brake on antiviral and autoimmune signaling.
• Negative regulators such as SOCS1, SESN1, TAX1BP1, and AHR act at distinct nodes of the cGAS-STING and IRF7 pathways to prevent excessive type I IFN.
• Loss of negative regulation causes interferonopathies, autoimmunity, and altered tumor immunity, making these genes attractive therapeutic targets.
• Plasmacytoid dendritic cells are the dominant type I IFN producers and are tightly controlled by negative feedback mechanisms.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of negative regulators in type I IFN production.
• Functional screens and bioinformatics have identified multiple negative regulators of the type I IFN pathway, expanding the candidate gene space.
Description
Type I interferons (IFN-I) are a family of cytokines that include IFN-alpha, IFN-beta, IFN-delta, IFN-epsilon, IFN-zeta, IFN-kappa, IFN-tau, and IFN-omega, and they are essential for antiviral defense and immune homeostasis. Because unrestrained IFN-I production can drive autoimmunity and inflammatory disease, cells deploy a dedicated set of negative regulatory processes that stop, prevent, or reduce IFN-I production. GO:0032480, negative regulation of type I interferon production, is the Gene Ontology term that captures this entire class of braking mechanisms. Mechanistically, negative regulation of type I IFN production operates at multiple levels, including degradation or sequestration of cGAS-STING pathway components, suppression of IRF7 activation, and feedback inhibition through SOCS proteins. For example, TAX1BP1-directed Golgiphagy limits STING signaling, while SESN1 negatively regulates STING1 to maintain innate immune homeostasis. Viral pathogens also exploit these brakes; duck Tembusu virus inhibits type I IFN production through a JOSD1-SOCS1-IRF7 negative-feedback pathway. For researchers, GO:0032480 provides a conceptual framework to study how cells avoid IFN-I overproduction and how this balance is broken in disease. The term is also practically important because negative regulators are candidate drug targets and biomarkers in lupus, cancer, and inborn errors of immunity. This article integrates the QuickGO definition with verified PubMed literature to summarize the mechanisms, key genes, disease links, and experimental models relevant to GO:0032480.
negative regulation of type I interferon production At A Glance
| GO ID | GO:0032480 |
|---|---|
| GO term | negative regulation of type I interferon production |
| Ontology | biological_process |
| Synonym | down regulation of type I interferon production; down-regulation of type I interferon production; downregulation of type I interferon production; inhibition of type I interferon production; negative regulation of type I IFN production |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of type I interferon production. |
| Type I IFN family members | Interferon-alpha, beta, delta, epsilon, zeta, kappa, tau, and omega gene families. |
| Representative negative regulators | SOCS1, SESN1, TAX1BP1, AHR, JOSD1, and additional screen-identified factors. |
| Key producing cell type | Plasmacytoid dendritic cells are major type I IFN producers under negative regulatory control. |
| Disease relevance | Interferonopathies, lupus, autoimmunity, and cancer immunity. |
What Is GO:0032480?
GO:0032480, negative regulation of type I interferon production, is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of type I interferon production. Type I interferons include the interferon-alpha, beta, delta, epsilon, zeta, kappa, tau, and omega gene families. In practice, this term covers molecular brakes that act on transcription, mRNA stability, protein stability, or signaling flux upstream of IFN-I genes, thereby limiting the amount of IFN-I released by a cell.
Why Is negative regulation of type I interferon production Important in Cell Biology?
Negative regulation of type I interferon production is important because it sets the threshold between protective antiviral immunity and harmful chronic inflammation. When this brake fails, excessive IFN-I can promote autoimmunity, as seen in inborn errors of histone pre-mRNA processing that cause cGAS-mediated IFN induction. Conversely, tumors can exploit negative regulators such as AHR to suppress STING-dependent IFN-I and diminish chemotherapy efficacy. Understanding GO:0032480 therefore informs both basic immunology and therapeutic strategies in autoimmunity and oncology.
• Prevents IFN-I overproduction that would otherwise drive autoimmunity and interferonopathies.
• Controls the magnitude and duration of antiviral responses in plasmacytoid dendritic cells and other cell types.
• Shapes T cell states in lupus, where IFN subverts an AHR-JUN axis to promote CXCL13+ T cells.
• Provides candidate targets for cancer therapy, since AHR-mediated suppression of STING-dependent IFN-I reduces chemotherapy efficacy.
• Explains how viruses such as duck Tembusu virus evade innate immunity via JOSD1-SOCS1-IRF7 feedback.
• Maintains innate immune homeostasis through SESN1-dependent negative regulation of STING1.
• Limits STING signaling via TAX1BP1-directed Golgiphagy, a negative feedback mechanism.
• Enables functional screens that identify new negative regulators of the type I IFN pathway.
• Supports development of CRISPR models to test causality of candidate negative regulators.
• Informs biomarker and drug discovery efforts in lupus, cancer, and interferon-driven diseases.
What Happens During negative regulation of type I interferon production?
Initiation of negative feedback after IFN-I sensing
In simple terms: Once cells detect danger and start making interferon, they also switch on brakes to stop the response from running away.
Negative regulation of type I IFN production is often initiated as a feedback response to upstream sensing of cytosolic DNA or RNA. In inborn errors of histone pre-mRNA processing, cGAS-mediated induction of type I interferon triggers counter-regulatory processes that limit IFN output. Plasmacytoid dendritic cells, which are specialized IFN-I producers, integrate these feedback signals to avoid excessive cytokine release. The initiation step therefore couples pathogen sensing to the activation of negative regulators.
Suppression of cGAS-STING signaling
In simple terms: The cGAS-STING alarm system is dampened by proteins that remove or recycle its components.
A major node of negative regulation is the cGAS-STING axis. SESN1 negatively regulates STING1 to maintain innate immune homeostasis, providing a direct brake on STING-dependent IFN-I production. TAX1BP1-directed Golgiphagy mediates negative feedback regulation of STING signaling, illustrating how selective autophagy of Golgi-associated STING limits pathway output. These mechanisms ensure that STING activation is transient and spatially controlled.
Inhibition of IRF7-driven transcription
In simple terms: IRF7 is a master switch for interferon genes, and negative regulators block or degrade it to reduce interferon production.
IRF7 is a key transcription factor for type I IFN genes, and its suppression is a central mechanism of GO:0032480. Duck Tembusu virus inhibits type I IFN production through the JOSD1-SOCS1-IRF7 negative-feedback regulation pathway, showing that SOCS1 can act upstream of IRF7 to reduce IFN-I. This example demonstrates how viral cues can hijack host negative regulatory machinery to suppress IFN-I.
AHR-JUN axis and immune cell modulation
In simple terms: The AHR-JUN axis changes how immune cells behave and can indirectly reduce or reshape interferon-driven responses.
The aryl hydrocarbon receptor (AHR) and JUN form an axis that influences T cell states in lupus, where interferon subverts this axis to promote CXCL13+ T cells. AHR also diminishes chemotherapy efficacy by suppressing STING-dependent type-I interferon in bladder cancer, linking AHR to negative regulation of IFN-I in tumors. These findings place AHR-JUN signaling within the broader network of GO:0032480.
Systems-level identification of negative regulators
In simple terms: Scientists use screens to find new brakes on the interferon pathway.
Screening and validation studies have identified multiple negative regulators of the type I interferon pathway, expanding the list of genes that can be assigned to GO:0032480. Such screens typically combine perturbation with IFN-I readouts to nominate candidates for mechanistic follow-up. This systems-level approach complements focused studies on individual regulators such as SESN1, TAX1BP1, and SOCS1.
Key Genes Involved in GO:0032480 negative regulation of type I interferon production
The following genes and proteins have been experimentally linked to negative regulation of type I interferon production (GO:0032480) in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SOCS1 | Suppresses IRF7-dependent type I IFN production as part of the JOSD1-SOCS1-IRF7 negative-feedback pathway. | Viral evasion and negative feedback studies. |
| SESN1 | Negatively regulates STING1 to maintain innate immune homeostasis. | STING-dependent IFN-I regulation and autophagy crosstalk. |
| TAX1BP1 | Directs Golgiphagy to mediate negative feedback regulation of STING signaling. | Selective autophagy and STING trafficking. |
| AHR | Suppresses STING-dependent type-I interferon and shapes T cell states in lupus. | Cancer chemotherapy efficacy and lupus immunology. |
| JUN | Part of the AHR-JUN axis subverted by interferon in lupus. | T cell differentiation and autoimmunity. |
| JOSD1 | Acts in the JOSD1-SOCS1-IRF7 pathway to inhibit type I IFN production. | Viral immune evasion mechanisms. |
| IRF7 | Master transcription factor for type I IFN genes; its inhibition reduces IFN-I production. | Transcriptional control of IFN-I. |
| STING1 | Signaling adaptor whose negative regulation limits IFN-I output. | cGAS-STING pathway modulation. |
| cGAS | DNA sensor whose activity can lead to type I IFN induction subject to negative regulation. | Inborn errors of histone pre-mRNA processing. |
| CXCL13 | T cell-associated chemokine promoted by IFN subversion of AHR-JUN in lupus. | Lupus T cell biology. |
| IFN-alpha family | Type I IFN genes whose production is reduced by GO:0032480 processes. | Interferonopathy and antiviral research. |
| IFN-beta | Type I IFN gene subject to negative regulation. | Antiviral and autoimmune models. |
| Plasmacytoid dendritic cell markers | Define the major IFN-I producing cell type under negative regulation. | pDC development and function. |
| Screen-identified negative regulators | Candidate genes that reduce type I IFN pathway activity. | Functional genomics of IFN-I. |
How Is negative regulation of type I interferon production Regulated?
Negative regulation of type I interferon production is itself regulated by feedback loops and post-translational mechanisms. SOCS1 provides a negative-feedback node upstream of IRF7, as shown in duck Tembusu virus infection. SESN1 controls STING1 stability or activity to maintain homeostasis, while TAX1BP1-directed Golgiphagy removes STING signaling components. AHR integrates environmental and metabolic signals to suppress STING-dependent IFN-I. These layers ensure that GO:0032480 is dynamically tuned rather than a simple on-off switch.
negative regulation of type I interferon production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| cGAS | Interferonopathy due to inborn errors of histone pre-mRNA processing | Knockout or point-mutation cell models with IFN-I readouts |
| AHR | Lupus T cell biology and bladder cancer chemotherapy response | Knockout and overexpression models in immune and cancer cell lines |
| SESN1 | Innate immune homeostasis via STING1 regulation | Knockout and tagged knock-in models for STING1 interaction |
| TAX1BP1 | STING signaling and Golgiphagy | Knockout models to assess STING degradation |
| SOCS1 | Viral evasion of type I IFN | Knockout and overexpression models in virus infection |
Interferonopathies and inborn errors of immunity
Inborn errors of histone pre-mRNA processing cause cGAS-mediated induction of type I interferon, indicating that failure of negative regulation contributes to interferonopathy. These conditions highlight how essential GO:0032480 is for preventing chronic IFN-I exposure.
Lupus and autoimmunity
In lupus, interferon subverts an AHR-JUN axis to promote CXCL13+ T cells, linking negative regulation of IFN-I to pathogenic T cell states. This suggests that restoring negative regulation could modulate autoimmune T cell responses.
Cancer and chemotherapy response
AHR diminishes the efficacy of chemotherapy via suppressing STING-dependent type-I interferon in bladder cancer. Thus, negative regulation of IFN-I can be exploited by tumors to evade immune control.
Viral immune evasion
Duck Tembusu virus inhibits type I interferon production through the JOSD1-SOCS1-IRF7 negative-feedback regulation pathway, illustrating how pathogens co-opt GO:0032480. Understanding these mechanisms may inform antiviral strategies.
From negative regulation of type I interferon production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase type I IFN production? | CRISPR knockout cell model with IFN-I reporter or ELISA |
| Does a specific phosphorylation site control negative regulator activity? | Point-mutation knock-in at the phosphosite |
| Where does a negative regulator localize during STING signaling? | Tagged knock-in with fluorescent or epitope tag |
| Can overexpression of a negative regulator suppress IFN-I? | Overexpression cell model with IFN-I readout |
| Which genes are negative regulators of the type I IFN pathway? | CRISPR library screening with IFN-I selection |
| How does AHR modulate STING-dependent IFN-I in cancer? | Knockout and overexpression in bladder cancer cell lines |
How to Study the negative regulation of type I interferon production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on type I IFN production | Identify negative regulators of IFN-I |
| Overexpression screen | Gain-of-function suppression of IFN-I | Validate candidate brakes |
| IFN-I reporter assay | Transcriptional activity of IFN-I promoters | Test regulators in cell lines |
| ELISA | Secreted IFN-alpha/beta protein levels | Quantify negative regulation |
| Imaging | Localization and degradation of STING | Study Golgiphagy and trafficking |
| RNA-seq | Global gene expression changes | Define IFN-stimulated gene signatures |
| Bioinformatics | Pathway and network enrichment | Prioritize GO:0032480 genes |
| Co-immunoprecipitation | Protein-protein interactions | Map negative regulator complexes |
CRISPR knockout and overexpression screens
Functional screens using CRISPR knockout or overexpression libraries can identify negative regulators of the type I IFN pathway, as demonstrated by screening and validation studies. These methods nominate candidate genes for GO:0032480 and prioritize them for mechanistic work.
Reporter assays and cytokine quantification
IFN-I reporter assays and cytokine quantification (e.g., ELISA) measure the output of negative regulation. Such readouts are used to validate hits from screens and to test individual regulators like SOCS1 and SESN1.
Imaging and trafficking analysis
Imaging of STING and Golgi markers can reveal how TAX1BP1-directed Golgiphagy removes signaling components, providing spatial insight into negative regulation. Tagged knock-in models enable live-cell tracking of these processes.
Transcriptomics and bioinformatics
RNA-seq and bioinformatic analyses of IFN-stimulated genes can define the transcriptional consequences of negative regulator loss or gain. These approaches help connect candidate genes to GO:0032480 at a systems level.
How CRISPR Can Be Used to Study GO:0032480 negative regulation of type I interferon production
Knockout
CRISPR knockout of candidate negative regulators can reveal whether they suppress type I IFN production. For example, knocking out SESN1 or TAX1BP1 may increase STING-dependent IFN-I, confirming their roles in GO:0032480. Knockout screens have been used to identify negative regulators of the type I IFN pathway.
Point Mutation
Point mutations can dissect specific residues required for negative regulator function, such as phosphorylation sites or interaction interfaces. This approach is valuable for proteins like STING1 and SESN1 where post-translational control is critical.
Knock-in
Tagged knock-in models allow tracking of endogenous negative regulators and their targets, such as STING during Golgiphagy. Knock-in of reporter cassettes can also provide sensitive readouts of IFN-I production.
Overexpression
Overexpression of candidate negative regulators can test whether they are sufficient to suppress type I IFN production. This is useful for validating SOCS1, AHR, and other brakes on IFN-I.
How EDITGENE Supports negative regulation of type I interferon production Research
Researchers studying negative regulation of type I interferon production-related genes often need to determine whether a candidate gene is causally involved in limiting IFN-I output, and CRISPR-based models provide a direct way to test this.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of type I interferon production research.
Frequently Asked Questions About negative regulation of type I interferon production
What is GO:0032480?
GO:0032480 is the Gene Ontology term for negative regulation of type I interferon production, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of type I interferon production.
What genes are involved in negative regulation of type I interferon production?
Genes include SOCS1, SESN1, TAX1BP1, AHR, JUN, JOSD1, IRF7, STING1, and cGAS, among others identified in screens.
How does STING signaling get negatively regulated?
STING signaling is negatively regulated by mechanisms such as SESN1-mediated control of STING1 and TAX1BP1-directed Golgiphagy that removes STING components.
Why is negative regulation of type I interferon production important in lupus?
In lupus, interferon subverts an AHR-JUN axis to promote CXCL13+ T cells, linking negative regulation of IFN-I to autoimmune T cell responses.
Can viruses inhibit type I interferon production?
Yes, duck Tembusu virus inhibits type I IFN production through the JOSD1-SOCS1-IRF7 negative-feedback pathway.
What role does AHR play in type I interferon regulation?
AHR diminishes chemotherapy efficacy by suppressing STING-dependent type-I interferon in bladder cancer and shapes T cell states in lupus.
How can I study negative regulators of type I IFN with CRISPR?
CRISPR knockout, point-mutation, knock-in, and overexpression models, as well as library screens, can be used to test candidate negative regulators.
What diseases are linked to defects in negative regulation of type I IFN?
Interferonopathies, lupus, autoimmunity, and cancer immune evasion have been linked to altered negative regulation of type I IFN.
What is the role of pDCs in type I interferon production?
Plasmacytoid dendritic cells are major producers of type I IFN and are subject to developmental and functional regulation.
How do I choose a model to study GO:0032480?
The choice depends on the question: knockout for loss-of-function, point mutation for residue-level analysis, knock-in for tagging, overexpression for sufficiency, and screens for discovery.
Conclusion
GO:0032480, negative regulation of type I interferon production, is a critical biological process that balances antiviral immunity and prevents harmful IFN-I overproduction. Key negative regulators such as SOCS1, SESN1, TAX1BP1, and AHR act at distinct nodes of the cGAS-STING-IRF7 network, and their dysfunction is linked to interferonopathies, lupus, and cancer. Researchers can leverage CRISPR knockout, point-mutation, knock-in, overexpression, and library screening approaches to dissect these mechanisms and identify new therapeutic targets. Continued work on GO:0032480 will clarify how cells maintain IFN-I homeostasis and how this balance can be restored in disease.
References
- 1. Uggenti C et al.. 2020. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing.. Nat Genet 52(12):1364-1372 PMID: 33230297
- 2. Reizis B. 2019. Plasmacytoid Dendritic Cells: Development, Regulation, and Function.. Immunity 50(1):37-50 PMID: 30650380
- 3. Law C et al.. 2024. Interferon subverts an AHR-JUN axis to promote CXCL13(+) T cells in lupus.. Nature 631(8022):857-866 PMID: 38987586
- 4. Pang Z et al.. 2025. Screening and Validation of Negative Regulators of the Type I Interferon Pathway.. Adv Biol (Weinh) 9(11):e00736 PMID: 40828666
- 5. Suklabaidya S et al.. 2026. Negative feedback regulation of STING signaling by TAX1BP1-directed Golgiphagy.. Nat Commun 17(1) PMID: 41673009
- 6. Xu L et al.. 2025. SESN1 negatively regulates STING1 to maintain innate immune homeostasis.. Autophagy 21(6):1245-1262 PMID: 39945079
- 7. Huang S et al.. 2022. Duck Tembusu Virus Inhibits Type I Interferon Production through the JOSD1-SOCS1-IRF7 Negative-Feedback Regulation Pathway.. J Virol 96(18):e0093022 PMID: 36069544
- 8. Ma Z et al.. 2023. AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer.. Nat Commun 14(1):5415 PMID: 37670034
